Study of a new drug for PNH when Soliris is not working well
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new investigational drug called NM8074 for people with PNH whose disease is not well controlled on Soliris. It aims to see if this new treatment can improve their anemia and reduce the need for blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and weigh at least 45 kg (about 99 pounds).
- You need a confirmed PNH diagnosis, with a large enough population of abnormal blood cells (at least 10%).
- You must have signs of ongoing red blood cell breakdown (hemolysis) and anemia, with hemoglobin typically below 10.5 g/dL.
- You need to have received at least one red blood cell transfusion in the past year.
- You must be currently treated with Soliris (eculizumab).
- You must be willing to get vaccinated against bacterial meningitis (or take preventive antibiotics) before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NM8074 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet been treated with complement inhibitors. The goal is to see if NM8074 can reduce red blood cell destruction and improve anemia, potentially reducing the need for blood transfusions.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
This trial tests a new combination of two drugs (pozelimab and cemdisiran) for adults with PNH whose current treatment (eculizumab, ravulizumab, or crovalimab) isn't controlling their symptoms well. It aims to see if the combination reduces red blood cell breakdown and improves blood counts.
This study tests a new pill (FXS6837) against a standard treatment (eculizumab) for people with PNH. The goal is to see if the pill is safe and effective in improving anemia and reducing the need for transfusions.
This trial is testing an experimental pill called NTQ5082 for people with PNH who haven't been treated with complement inhibitors before. The goal is to see if it can improve anemia and control PNH symptoms like fatigue and blood clots.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.